ERBB2 and cancer: An analysis of sequencing data from approximately 111,000 tumors, encompassing around 400 types or subtypes of cancer, has found numerous recurring somatic point mutations in the transmembrane and juxtamembrane domains of HER2, resulting in the substitutions of amino acids.